☆ 4.7 Meeting Abstract

Safety Profile of Venetoclax Monotherapy in Patients with Chronic Lymphocytic Leukemia

BLOOD (2016)

Get Full Text
Add to Collection

Journal

BLOOD
Volume 128, Issue 22, Pages -

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood.V128.22.4395.4395

Keywords

-

Categories

Hematology

Funding

  1. AbbVie Inc.
  2. Genentech
  3. Janssen
  4. Pharmacyclics
  5. Infinity
  6. TG Therapeutics
  7. AbbVie
  8. Servier
  9. GSK
  10. Mundipharma
  11. Celgene
  12. Gilead
  13. Roche
  14. Novartis
  15. Acerta
  16. Sanofi
  17. Boehringer Ingelheim
  18. Hoffmann-La Roche
  19. Amgen
  20. Genzyme

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.